PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Neurosurg Focus. Author manuscript; available in PMC 2017 August 8.
Published in final edited form as:
PMCID: PMC5548126
NIHMSID: NIHMS887866

Pathological characteristics of spine metastases treated with high-dose single-fraction stereotactic radiosurgery

Abstract

OBJECTIVE

Spine radiosurgery is increasingly being used to treat spinal metastases. As patients are living longer because of the increasing efficacy of systemic agents, appropriate follow-up and posttreatment management for these patients is critical. Tumor progression after spine radiosurgery is rare; however, vertebral compression fractures are recognized as a more common posttreatment effect. The use of radiographic imaging alone posttreatment may make it difficult to distinguish tumor progression from postradiation changes such as fibrosis. This is the largest series from a prospective database in which the authors examine histopathology of samples obtained from patients who underwent surgical intervention for presumed tumor progression or mechanical pain secondary to compression fracture. The majority of patients had tumor ablation and resulting fibrosis rather than tumor progression. The aim of this study was to evaluate tumor histopathology and characteristics of patients who underwent pathological sampling because of radiographic tumor progression, fibrosis, or collapsed vertebrae after receiving high-dose single-fraction stereotactic radiosurgery.

METHODS

Between January 2005 and January 2014, a total of 582 patients were treated with linear accelerator–based single-fraction (18–24 Gy) stereotactic radiosurgery. The authors retrospectively identified 30 patients (5.1%) who underwent surgical intervention for 32 lesions with vertebral cement augmentation for either mechanical pain or instability secondary to vertebral compression fracture (n = 17) or instrumentation (n = 15) for radiographic tumor progression. Radiation and surgical treatment, histopathology, and long-term outcomes were reviewed. Survival and time to recurrence were calculated using the Kaplan-Meier method.

RESULTS

The mean age at the time of radiosurgery was 59 years (range 36–80 years). The initial pathological diagnoses were obtained for all patients and primarily included radioresistant tumor types, including renal cell carcinoma in 7 (22%), melanoma in 6 (19%), lung carcinoma in 4 (12%), and sarcoma in 3 (9%). The median time to surgical intervention was 24.7 months (range 1.6–50.8 months). The median follow-up and overall survival for all patients were 42.5 months and 41 months (overall survival range 7–86 months), respectively. The majority of assessed lesions showed no evidence of tumor on pathological review (25 of 32, 78%), while a minority of lesions revealed residual tumor (7 of 32, 22%). The median survival for patients after tumor recurrence was 5 months (range 2–70 months).

CONCLUSIONS

High-dose single-fraction radiosurgery is tumor ablative in the majority of instances. In a minority of cases, tumor persists and salvage treatments should be considered.

Keywords: spine stereotactic radiosurgery, image-guided radiation therapy, pathological correlation, radiation fibrosis, tumor ablation

More than 20% of cancer patients will develop metastatic disease in the spine. Local control of metastatic spine lesions is accomplished by radiation therapy, surgery, or a combination of both modalities. The actuarial control rates with high-dose single-fraction stereotactic radiosurgery (SRS) are ≥ 90%.17 Advances in systemic therapy have led to improvement in survival for metastatic cancer patients and have made durable control with minimal toxicity imperative for patients. In the longest series to date (median follow-up 6.1 years), long-term survivors post–spinal radiosurgery were identified and analyzed. In that series, spine radiosurgery resulted in a durable 5-year local control rate of more than 90%. Moreover, the safety profile of high-dose spinal radiosurgery was encouraging: there was no Grade 3 or greater toxicity in the long-term survivors. The radiographic vertebral compression fracture (VCF) rate, however, was reported at 36%.12

The most common complication of radiosurgery is VCF. The incidence of VCF varies widely in the literature. Our institution was one of the first to report on VCF incidence, with a radiographic VCF rate of 39% and median time to VCF of 25 months for 71 lesions treated with single-fraction radiosurgery.14 In contrast, in another large series by Boehling et al. of 123 lesions, the VCF rate was 20% and the median time to VCF was much shorter at 3 months.4 In a pooled multiinstitutional analysis examining 410 lesions, the incidence of 1- and 2-year fracture rates was 12.35% and 13.49%, respectively. The median time to fracture was shorter at 2.46 months.15 A major outcome from the study was the impact of dose per fraction on the subsequent development of VCF, namely that the VCF rates at 1 year were 39% for ≥ 24 Gy and 10% for ≤ 19 Gy. The mechanism underlying VCF may be elucidated by examining the pathological features. The late development of VCF with high-dose single-fraction radiosurgery is thought to develop secondary to radiation as a major contributing factor, specifically fibrosis and necrosis within the tumor and bone that weaken the vertebral body.1

The surgical salvage stabilization procedure rate of VCF after radiosurgery varies widely in the literature and is in the range of 11%–58%.14,16 The vast majority of patients receive vertebral cement augmentation (kyphoplasty or vertebroplasty), yet up to 25% may require instrumented surgical intervention for instability.

A small subset of patients, however, requires surgical salvage if there is evidence of radiographic tumor progression. Distinguishing between fibrosis and tumor recurrence in the postradiosurgery setting has significant therapeutic implications. This is the largest reported experience examining the histopathology of post–spinal radiosurgery requiring surgical intervention. In this study, we examine the pathological outcomes, local control, and overall survival in these patients.

Methods

Patient Characteristics

Between January 2005 and January 2014, 582 patients were treated with high-dose single-fraction linear accelerator–based radiosurgery for spinal metastases at Memorial Sloan Kettering Cancer Center. Patients were offered SRS in accordance with the NOMS (neurological, oncological, mechanical, and systemic) multidisciplinary decision framework.2 Clinical data including date of radiosurgery and interval between administration of radiosurgery and surgical instrumentation were collected after receiving approval from the institutional review board.

Radiosurgery Technique

The decision to treat with SRS was made by a multidisciplinary tumor board consisting of spine surgeons, neuroradiologists, and radiation oncologists. The immobilization and planning technique at Memorial Sloan Kettering Cancer Center has been previously described.10,11 Clinical target volumes were delineated using consensus guidelines. An intensity-modulated radiation therapy (IMRT) plan was then generated (planning target volume [PTV]) to treat to a prescription of 18–24 Gy, prescribed to an isodose line that best achieved planning objectives, normalized to 100%. Systemic chemotherapy was discontinued for 1–2 weeks prior to image-guided IMRT. Cone-beam CT was used for image-guided IMRT treatment position verification.

Surgery

Surgical intervention was considered when VCF resulted in gross spinal instability not amenable to percutaneous cement augmentation or high-grade radiographic epidural spinal cord compression. If surgical instrumentation was not indicated, vertebral cement augmentation was performed in symptomatic patients. Vertebral cement augmentation was used primarily in symptomatic patients with at least 50% vertebral body collapse, lytic lesions, and without radiculopathy or posterior element disease. In addition, the patient’s performance status and extent of metastatic tumor burden were considered when deciding on surgical salvage options.

Follow-Up and Clinical End Points

After treatment, follow-up imaging was performed using serial MRI. In some instances, PET CT was performed to complement serial MRI. The patients were seen at regular intervals by multidisciplinary teams involving radiation oncologists, neuroradiologists, and spine surgeons. End points examined included radiographic images suggestive of local treatment failure, salvage surgical intervention, pathological characteristics, as well as overall survival.

Patient survival and salvage intervention were calculated from the time of radiation therapy until the last clinic visit or death. Patients typically underwent follow-up every 12–16 weeks after treatment with image-guided IMRT using routine total spine MR images. Local treatment failure was defined as disease progression within the treated segment of the spine.

Histopathological Analysis

Specimens obtained at the time of instrumentation surgery as well as vertebral cement augmentation underwent histological examination. All tissue was formalin-fixed, decalcified when necessary, and processed routinely, and H & E stains were prepared. In every case, the study pathologist (N.P.A.) reexamined all slides, and the presence of viable tumor, as well as necrotic tumor, and fibrosis was recorded. In 7 cases the tumor proliferation rate (MIB-1 labeling index) was examined by immunohistochemistry using antibody specific to KI-67 (M7240, 1:200; Dako).

Results

Between 2005 and 2014, 30 consecutive patients with 32 lesions underwent interventions after SRS as shown in Table 1. Interventions included vertebral cement augmentation for VCF or instrumentation for presumed radiographic progression. The mean age at the time of radiosurgery was 59 years (range 36–80 years). The initial pathological diagnoses were obtained for all patients and primarily included radioresistant histologies, including renal cell carcinoma in 7 (22%), malignant melanoma in 6 (19%), lung carcinoma in 4 (12%), and sarcoma in 3 (9%). Radiosensitive histologies that received treatment included breast carcinoma in 3 (9%) and prostate carcinoma in 3 (9%). Spinal levels treated included thoracic in 8 patients (25%), thoracolumbar in 4 (12%), and lumbar in 20 (62%). The majority of patients (91%) received single-fraction high-dose radiosurgery to 24 Gy, with the remaining patients (9%) receiving single-fraction 18- to 22-Gy radiosurgery. One of the patients receiving 24 Gy subsequently received a second course of radiotherapy to 27 Gy in 3 fractions followed by surgical instrumentation; thus, the cumulative total dose received by 1 patient was 51 Gy. The dosimetry of the treated lesions was satisfactory. The mean PTV was 142 cm3 (range 32.48–368.2 cm3). The mean gross tumor volume minimum dose was 16.7 Gy (range 11.3–24.4 Gy), and the mean PTV minimum dose was 14.4 Gy (range 10.6–23.5 Gy).

TABLE 1
Baseline clinical characteristics (overall n = 30 patients, 32 lesions)

The median time to intervention was 24.7 months (range 1.6–50.8 months). The majority of lesions necessitated percutaneous cement augmentation techniques (n = 17), and the remaining lesions (n = 15) required invasive surgical instrumentation. The majority of salvage procedures (n = 22) were performed to treat VCF. Of these, only 1 patient had evidence of viable tumor; otherwise, all other lesions demonstrated fibrosis and/or necrosis. There were 10 lesions with evidence of radiographic tumor progression on MRI that underwent surgical intervention, with only 6 revealing evidence of tumor on pathological review. Only 11 patients (11 lesions) underwent PET CT scanning after radiosurgery and prior to intervention. Of these patients, the majority (9 patients) had no evidence of disease pathologically. In these patients, PET CT was equivocal in some instances with a standardized uptake value (SUV) increase observed with compression fractures in the range of 2.2–6.3. In the remaining 2 cases with persistent disease, the available PET CT information was of limited utility. In 1 case, PET was performed 5 months prior to pathological confirmation of disease, and the SUV was only 3.1. In the second case, PET was performed after the second course of radiosurgery and revealed an SUV of only 3.8. In this patient, MRI revealed tumor progression, which was confirmed pathologically 1 month later. A summary of the patient characteristics with residual disease postradiosurgery is shown in Table 2.

TABLE 2
Cases with viable tumor on pathological review postradiosurgery treatment

The majority of assessed lesions showed complete fibrosis and/or necrosis with no evidence of tumor on pathological review (n = 25; 78%). A minority of lesions, however, revealed residual tumor (n = 7; 22%). The median follow-up was 42.5 months, and the median overall survival for the entire cohort was 41 months (range 7–86 months; Fig. 1 upper). The median time to recurrence was 6 months (range 2–39 months). For patients who experienced recurrence, the median overall survival after recurrence was 5 months (range 2–70 months; Fig. 1 lower). Examples of lesions with viable tumors are shown in Fig. 2B and D. For the pathology specimens revealing no evidence of residual disease, there was evidence of fibrosis (n = 18) and necrosis (n = 7) as shown in Fig. 2A and C.

FIG. 1
Upper: Overall survival. Kaplan-Meier analysis for survival in patients treated with single-fraction radiosurgery for spinal metastases who underwent surgical intervention with either vertebral cement augmentation or surgical instrumentation (n = 32). ...
FIG. 2
Photomicrographs of pathology specimens following single-fraction high-dose image-guided radiotherapy. A: Kyphoplasty specimen revealing acellular bone with fibrosis from a patient with melanoma treated with 24 Gy to L-3. B: Specimen from instrumentation ...

Discussion

It is well established that for radioresistant cancers, the use of single-fraction SRS has resulted in excellent actuarial local control rates of greater than 90%.3,17 While the risk of radiation myelopathy is low, the reported rates of VCF are much greater and vary widely from 11% to 39% with the median time to VCF ranging from 2 to 25 months.4,5,14 The variation in the literature may be partly attributable to the definition of fracture, which includes both fracture progression as well as incidence of new VCFs. In a recent large multiinstitutional pooled analysis of more than 410 patients, the fracture rate was reported to be 14.5% with a median time to fracture of 2.46 months; however, only 47% of fractures were new. In addition, while radiographic VCF is concerning and patients often require significantly higher narcotic use, identifying the salvage intervention rate becomes essential. In our previously reported series of fracture risk after SRS, while the overall radiographic VCF rate was 39%, less than 11% of patients who developed fracture required salvage surgical intervention with either instrumentation or kyphoplasty. This is consistent with the current study in which the surgical intervention rate was only 5% and acceptable.

While radiographic findings suggestive of VCF progression are straightforward, radiographic findings suggestive of tumor recurrence as the etiology for VCF are not as robust. In this analysis, less than 5% of VCF cases exhibited active tumor. There are limited guidelines as to the use of biological imaging such as PET that accurately distinguish disease progression from radiation treatment imaging effects. The FDG uptake by tumors on PET CT is variable and largely dependent on tumor histology. The use of MRI alone in determining local recurrence in the spine is less reliable. Just as with radiosurgery of the brain, posttreatment radiation changes may be difficult to discern from tumor recurrence.8 In a recent case report by Al-Omair et al.,1 2 patients underwent tissue sampling after radiographic findings suggested worsening VCF and increased T1 signal intensity on MRI suggested tumor recurrence. In this review, both cases revealed necrotic debris, fibrosis, and avital bone, with 1 case showing fragments of adenocarcinoma. In this series, the significance of tissue sampling was emphasized to differentiate tumor from radiation-induced fibrosis and necrosis, which was attributed as the cause of VCF. In a recent study examining pathological outcomes in patients requiring operative intervention after SRS, viable tumor was found in the periphery of the resected specimens in 60% of cases.18 In this analysis, 6 of 10 patients who underwent surgery for suspected tumor recurrence were found to have pathological evidence of tumor recurrence; the other cases were found to be fibrosis and/or necrosis only. In our current study, only 22% of assessed lesions revealed viable tumor. The majority of lesions treated with high-dose single-fraction radiosurgery, however, showed no evidence of tumor on pathological review (78%), resulting in complete tumor ablation.

It is well established that radiation dose is a significant predictor of local control and potential local cure for spinal metastases.17 Prior studies on radiosurgery have demonstrated that a dose greater than 20 Gy results in high local control rates in the lung, liver, and brain. It is thought that tumor tissue stem cells exposed in vivo to fractions greater than 8–10 Gy respond via a different response mechanism and that high single-dose exposure (≥ 15 Gy) is linked to the induction of microvascular endothelial apoptosis.7 Moreover, in recent studies, radiation dose also appears to have a synergistic role in the immune response.6 In preclinical mouse models, while both high-dose radiotherapy in the range of 15–20 Gy × 1–3 fractions and lower dose 3–5 Gy × 4–5 fractions resulted in higher T-cell infiltration, only high-dose radiotherapy resulted in significantly higher tumor growth delay.13 There is increasing interest in harnessing the radioablative doses of radiation to stimulate the immune system. In a recent prospective randomized study of castrate-resistant metastatic prostate cancer in which patients received single-fraction 8-Gy radiotherapy to bone followed by checkpoint blockade immunotherapy (CTLA4 inhibition), there was suggestion of survival benefit (22.7 months vs 15.8 months [p = 0.0038]) in a subset of patients with favorable features and lower disease burden including alkaline phosphatase less than 1.5 upper limit of normal and no visceral metastases.9 It is highly suggestive that more patients would have responded if radioablative doses of radiation had been administered. This study contributes to the histopathological analyses in the literature confirming that ablation and tumor sterilization comes about postradiosurgery. Future studies are needed to harness the power of radiosurgical tumor ablation in combination with immunotherapy.

Limitations of our study include the small patient number and the possibility of sampling error from cement vertebral augmentation tissue specimens. Nonetheless, this is the largest series reporting on pathological outcomes after SRS to the spine. Our findings suggest that while radiation fibrosis and osteonecrosis may be a contributing factor to VCF, the incidence of salvage surgical interventions in these patients is low and acceptable. Moreover, locally curative radiation therapy and durable tumor ablation are critical via high-dose single-fraction radiosurgery.

Conclusions

This study demonstrates that SRS is an effective tumor ablative treatment for spinal metastases as evidenced by pathological tissue sampling. The incidence of salvage interventions for symptomatic VCFs is low. The majority of lesions treated had locally ablative, curative, and durable control as evidenced on pathological examination. More accurate methods of radiographic surveillance need to be developed to diagnose local recurrence after spine radio-surgery.

ABBREVIATIONS

IMRT
intensity-modulated radiation therapy
PTV
planning target volume
SRS
stereotactic radiosurgery
SUV
standardized uptake value
VCF
vertebral compression fracture.

Footnotes

Disclosures

The authors report the following. Dr. Laufer: consultant for Globus, DePuy/Synthes, and SpineWave. Dr. Yamada: consultant for Varian Medical Systems and medical advisory board member for the Chordoma Foundation.

Author Contributions

Conception and design: Yamada, Katsoulakis, Laufer, Bilsky. Acquisition of data: Yamada, Katsoulakis, Laufer, Bilsky. Analysis and interpretation of data: all authors. Drafting the article: Yamada, Katsoulakis. Critically revising the article: all authors. Reviewed submitted version of manuscript: all authors. Approved the final version of the manuscript on behalf of all authors: Yamada. Statistical analysis: Katsoulakis, Laufer, Lovelock. Administrative/technical/material support: Katsoulakis, Bilsky. Study supervision: Yamada, Laufer, Bilsky. Pathology review: Agaram.

References

1. Al-Omair A, Smith R, Kiehl TR, Lao L, Yu E, Massicotte EM, et al. Radiation-induced vertebral compression fracture following spine stereotactic radiosurgery: clinicopathological correlation. J Neurosurg Spine. 2013;18:430–435. [PubMed]
2. Bilsky M, Smith M. Surgical approach to epidural spinal cord compression. Hematol Oncol Clin North Am. 2006;20:1307–1317. [PubMed]
3. Bishop AJ, Tao R, Rebueno NC, Christensen EN, Allen PK, Wang XA, et al. Outcomes for spine stereotactic body radiation therapy and an analysis of predictors of local recurrence. Int J Radiat Oncol Biol Phys. 2015;92:1016–1026. [PubMed]
4. Boehling NS, Grosshans DR, Allen PK, McAleer MF, Burton AW, Azeem S, et al. Vertebral compression fracture risk after stereotactic body radiotherapy for spinal metastases. J Neurosurg Spine. 2012;16:379–386. [PubMed]
5. Cunha MV, Al-Omair A, Atenafu EG, Masucci GL, Letourneau D, Korol R, et al. Vertebral compression fracture (VCF) after spine stereotactic body radiation therapy (SBRT): analysis of predictive factors. Int J Radiat Oncol Biol Phys. 2012;84:e343–e349. [PubMed]
6. Franceschini D, Franzese C, Navarria P, Ascolese AM, De Rose F, Del Vecchio M, et al. Radiotherapy and immunotherapy: Can this combination change the prognosis of patients with melanoma brain metastases? Cancer Treat Rev. 2016;50:1–8. [PubMed]
7. Garcia-Barros M, Paris F, Cordon-Cardo C, Lyden D, Rafii S, Haimovitz-Friedman A, et al. Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science. 2003;300:1155–1159. [PubMed]
8. Jagannathan J, Bourne TD, Schlesinger D, Yen CP, Shaffrey ME, Laws ER, Jr, et al. Clinical and pathological characteristics of brain metastasis resected after failed radiosurgery. Neurosurgery. 2010;66:208–217. [PubMed]
9. Kwon ED, Drake CG, Scher HI, Fizazi K, Bossi A, van den Eertwegh AJ, et al. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2014;15:700–712. [PMC free article] [PubMed]
10. Laufer I, Iorgulescu JB, Chapman T, Lis E, Shi W, Zhang Z, et al. Local disease control for spinal metastases following “separation surgery” and adjuvant hypofractionated or high-dose single-fraction stereotactic radiosurgery: outcome analysis in 186 patients. J Neurosurg Spine. 2013;18:207–214. [PubMed]
11. Lovelock DM, Hua C, Wang P, Hunt M, Fournier-Bidoz N, Yenice K, et al. Accurate setup of paraspinal patients using a noninvasive patient immobilization cradle and portal imaging. Med Phys. 2005;32:2606–2614. [PubMed]
12. Moussazadeh N, Lis E, Katsoulakis E, Kahn S, Svoboda M, DiStefano NM, et al. Five-year outcomes of high-dose single-fraction spinal stereotactic radiosurgery. Int J Radiat Oncol Biol Phys. 2015;93:361–367. [PubMed]
13. Patel KR, Lawson DH, Kudchadkar RR, Carthon BC, Oliver DE, Okwan-Duodu D, et al. Two heads better than one? Ipilimumab immunotherapy and radiation therapy for melanoma brain metastases. Neuro Oncol. 2015;17:1312–1321. [PMC free article] [PubMed]
14. Rose PS, Laufer I, Boland PJ, Hanover A, Bilsky MH, Yamada J, et al. Risk of fracture after single fraction image-guided intensity-modulated radiation therapy to spinal metastases. J Clin Oncol. 2009;27:5075–5079. [PMC free article] [PubMed]
15. Sahgal A, Atenafu EG, Chao S, Al-Omair A, Boehling N, Balagamwala EH, et al. Vertebral compression fracture after spine stereotactic body radiotherapy: a multi-institutional analysis with a focus on radiation dose and the spinal instability neoplastic score. J Clin Oncol. 2013;31:3426–3431. [PubMed]
16. Sung SH, Chang UK. Evaluation of risk factors for vertebral compression fracture after stereotactic radiosurgery in spinal tumor patients. Korean J Spine. 2014;11:103–108. [PMC free article] [PubMed]
17. Yamada Y, Bilsky MH, Lovelock DM, Venkatraman ES, Toner S, Johnson J, et al. High-dose, single-fraction image-guided intensity-modulated radiotherapy for metastatic spinal lesions. Int J Radiat Oncol Biol Phys. 2008;71:484–490. [PubMed]
18. Zwagerman NT, McDowell MM, Hamilton RL, Monaco EA, III, Flickinger JC, Gerszten PC. Histopathological examination of spine tumors after treatment with radiosurgery. Neurosurg Focus. 2016;41(2):E14. [PubMed]